Abstract
The recognition of Acute Leukemia as a malignancy of the blood cells is usually credited to Virchow [1] as is the term Leukemia (Weisses Blut) [2]. The following century provided extensive details of the pathology and cytology of this disorder. But, the first mention of any attempt to alter its natural history was reported in 1948 by Dr. Farber. He described temporary remissions of the disease and reported that the disease almost invariably recurred despite continuous administration of aminopterin [3]. In 1949, Pearson reported cortisone-induced regressions of lymphoid tumors [4], which was confirmed by Dr. Farber in 1950 showing remissions in childhood acute leukemia [5]. Following the Nobel prize winning research of Hitchings and Elion on the biochemistry of purine analogs [6], Dr. Burchenal reported remissions in acute leukemia with 6-mercaptopurine in 1953 [7]. Despite having three (3) unique molecules effective in inducing temporary remission in patients with acute leukemia, a careful review of the natural history of the disease was published by McMann and Foreman in 1957. They showed that, for over 600 patients studied between 1943 and 1952, the median survival was approximately 6 weeks and 95 % of the patients were dead by 12 months after diagnosis [8]. In 1955, the largest and most authoritative group in hematology, Dr. Wintrobe’s group in Utah reported, “It was not possible to demonstrate that the newer therapies (folic acid antagonists, ACTH, cortisone, and 6-mercaptopurine) significantly increased the total survival in these representative groups” [9]. In fact, the authors recommended that these therapies not be administered to patients since they were simply prolonging the horrible clinical manifestations of a uniformly fatal disease.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Freireich EJ, Lemak NA. Milestones in Luekemia Research & Therapy. London: The John Hopkins University Press; 1991.
Virchow R. Weisses Blut. Neue Notizen Gebiete Natur-Heilkunde 1845;36:151–7.
Farber S, Daimond LK, Mercer RD, et al. Temporary remission in acute leukemia in children prolonged by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N Engl J Med. 1948;238:787–93.
Pearson OH, Eliel LP, Rawson RW, et al. ACTH- and cortisone-induced regression of lymphoid tumors in man. Cancer. 1949;2:943–5.
Farber S, Shwachman H, Toch R et al. The effect of ACTH in acute leukemia in childhood. In Proceedings of the First Clinical ACTH Conference, Mote JR editor. Philadelphia: Blakiston; 1950:328–30.
Hitchings GH, Elion GB. The chemistry and biochemistry of purine analogs. Ann NY Acad Sci. 1954;60:195–9.
Burchenal JH, Murphy ML, Ellison RR, et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood. 1953;8:965–99.
MacMahon B, Forman D. Variation and duration of survival of patients with acute leukemia. Blood. 1957;12:683–93.
Haut A, Altman SJ, Cartwright GE, Wintrobe MM. The influence of chemotherapy on survival in actute leukemia. Blood. 1955;10:875–95.
Holland JF, Frei E III, Burchenal JH. Criteria for the evaluation of response to therapy of acute leukemia. In Proceedings of the Fourth Congress of the International Society for Hematology, Boston; 1956:213.
Frei III E, Holland JF, Schneiderman MA, Pinkel D, Selkirk G, Freireich EJ, Silver RT, Gold GL, Regelson W. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958;13:1126–48.
Frei III E, Freireich EJ, Gehan E, Pinkel D, Holland JF, Selawry O, Haurani F, Spurr CL, Hayes DM, James GW, Rothberg H, Sodee DB, Rundles RW, Schroeder LR, Hoogstraten B, Wolman IJ, Traggis DG, Cooper T, Gendel BR, Ebaugh F, Taylor R. Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood. 1961;18:431–54.
Shnider BI, Frei III E, Tuohy JH, Gorman J, Freireich EJ, Brindley Jr CO, Clements J. Clinical studies of 6-azauracil. Cancer Res. 1960;20:28–33.
Freireich EJ, Frei III E, Holland JF, Pinkel D, Selawry O, Rothberg H, Haurani F, Taylor R, Gehan EA. Evaluation of a new chemotherapeutic agent in patients with “advanced refractory” acute leukemia. Studies of 6-azauracil. Blood. 1960;16:1268–78.
Freireich EJ, Gehan EA, Frei III E, Schroeder LR, Wolman IJ, Anbari R, Burgert EO, Mills SD, Pinkel D, Selawry OS, Moon JH, Gendel BR, Spurr CL, Storrs R, Haurani F, Hoogstraten B, Lee S. The effect of 6-mercaptopurine on the duration of steroid-induced remissions in acute leukemia: A model for evaluation of other potentially useful therapy. Blood. 1963;21:699–716.
Karon MR, Freireich EJ, Frei III E. A preliminary report of vincristine sulphate—A new active agent for the treatment of acute leukemia. Pediatrics. 1962;30:791–6.
Freireich EJ, Frei III E. Recent advances in acute leukemia. In: Moore CV, Brown EB, editors. Progress in hematology. New York: Grune and Stratton; 1964. p. 189–202.
Frei III E, Freireich EJ. Progress and perspectives in the chemotherapy of acute leukemia. In: Goldin A, Hawking F, Schnitzer RJ, editors. Advances in chemotherapy, vol. 2. New York: Academic; 1965. p. 269–98.
Freireich EJ, Henderson ES, Karon M, Frei E III. The treatment of acute leukemia considered with respect to cell population kinetics. In: Proliferation and Spread of Neoplastic Cells, The University of Texas M.D. Anderson Cancer Center, 21st Annual Symposium on Fundamental Cancer Research. Baltimore: The Williams and Wilkins Co; 1968; 441–453.
Pui CH, Pei D, et al. Long term results of St. Jude. Total Therapy Studies for childhood ALL. Leukemia. 2010;24:371–82.
Freireich EJ, Gehan EA, Sulman D, Boggs DR, Frei III E. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis. 1961;14:593–608.
Dameshek W, Necheles TF, Finkel HE, Allen DM. Therapy of acute leukemia, 1965. Blood. 1965;26:220–5.
Talley RW, Viatkevicius VK. Megaloblastosis produced by a cytosine antagonist 1-B-D-arabinofuranosylcytosine. Blood. 1963;21:352–62.
Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: Useful agent in the treatment of acute leukemia in adults. Blood. 1968;32:507–21.
Skipper HE, Schabel Jr FM. Wilcox WS. Experimental evaluation of potential anticancer agents: XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemic cells. Cancer Chemother Rep. 1967;51:125–41.
Freireich EJ, Bodey GP, Harris JE, Hart JS. Therapy for acute granulocytic leukemia. Cancer Res. 1967;27:2573–7.
Frei III E, Bickers JN, Hewlett JS, et al. dose schedule and antitumor studies or arabinosyl cytosine. Cancer Res. 1969;29:1325–32.
Bickers JN, Gehan EA, Freireich EJ, Coltman CA, Wilson HE, Hewlett JS, Stuckey JW, Van Slyck EJ. Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response. Arch Intern Med. 1974;133:251–9.
DiMarco A, Gaetani M, Orezzi P et al. Antitumor activity of a new antibiotic: Daunomycin. In Proceedings of the Third International Congress of Chemotherapy, vol.2. Stuttgart, 1963; New York: Hafner;1964: 1023–1031.
DiMarco A, Gaetani M, Scarpinato B. Adriamycin: A new antibiotic with antitumor activity. Cancer Chemother Rep. 1969;53:33–7.
Yates JW, Wallace Jr J, Ellison RR, Holland JF. Cytosine arabinosyl and daunorubicin in acute non-lymphocytic leukemia. Cancer Chemother Rep. 1973;57:485.
Crosby WH. Grounds for optimism in treating actue granulocytic luekemia. Arch Intern Med. 1974;184:177.
Freireich EJ. Grounds for optimism in treating acute granulocytic leukemia (adult acute leukemia). Symposium on leukemia. Arch Intern Med. 1976;136:1375–6.
Bodey GP, Coltman CA, Hewlett JS, Freireich EJ. Progress in the treatment of adults with acute leukemia. Symposium on Leukemia. Arch Intern Med. 1976;136:1383–8.
Freireich EJ, Bodey GP, McCredie KB, Hersh EM, Gehan EA, Hart JS, Gutterman JU, Rodriguez V, Smith T, Hester JP. Developmental therapy in adult acute leukemia. Symposium on Leukemia. Arch Intern Med. 1976;136:1417–21.
Keating MJ, Smith TL, McCredie KB, Bodey GP, Hersh EM, Gutterman JU, Gehan E, Freireich EJ. A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer. 1981;47:2779–88.
Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E, Freireich EJ. Improved prospects for long-term survival in adults with acute myelogenous leukemia. J Am Med Assoc. 1982;248:2481–6.
Trujillo JM, Cork A, Ahearn MJ, Youness EL, McCredie KB. Hematologic and cytologic characterization of 8:21 translocation acute granulocytic leukemia. Blood. 1979;53:659.
Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Res. 1987;11:119–33.
Ravandi F, Estey E, Jones D, Faderl S, et al. Effective treatment of acute promyelocytic leukemia with a trans-retinoic acid, arsenic trioxide, and gemtuzumab ozoga. J Clin Oncol. 2009;27(4):504–10.
Ed T, Storb R, Clift RA, et al. Bone marrow transplantation: Part I. N Engl J Med. 1975;292:832–43.
Mathé G, Jammet H, Pendic B, et al. Transfusions et greffes de moelle osseuse homologue chez des humains irradiés à haute dos accidentellement. Rev Fr Etudes Clin Biol. 1959;4:226–38.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Freireich, E.J. (2013). History of Acute Leukemia. In: Wiernik, P., Goldman, J., Dutcher, J., Kyle, R. (eds) Neoplastic Diseases of the Blood. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3764-2_13
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3764-2_13
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3763-5
Online ISBN: 978-1-4614-3764-2
eBook Packages: MedicineMedicine (R0)